page image

Cardiomyopathie

Referenties

  1. Piano MR: ‘Alcoholic cardiomyopathy: Incidence, clinical characteristics, and pathophysiology’; Chest 121:1638-50, 2002.
  2. Regan TJ et al: ‘The role of ethanol in cardiac disease’; Annu. Rev. Med. 28:393-409, 1977.
  3. Djoenaidi W et al: ‘Beriberi cardiomyopathy’; Eur. J. Clin. Nutr. 46(3):227-232, 1992.
  4. Singh RB et al: ‘Dietary intake and plasma levels of antioxidant vitamins in health and disease: a hospital-based case-control study’; J. Nutr. Environ. Med. 5:235-242, 1995.
  5. Romero-Alvira D et al: ‘Cardiomyopathies and oxidative stress’; Med. Hypotheses 47(2):137-144, 1996.
  6. Redetzki JE et al: ‘Amelioration of cardiotoxic effects of alcohol by vitamin E’; J. Toxicol. Clin. Toxicol. 20(4):319-331, 1983.
  7. Freedman AM et al: ‘Magnesium deficiency-induced cardiomyopathy: Protection by vitamin E’; Biochem. Biophys. Res. Commun. 170(3):1102-1106, 1990.
  8. Li Y et al: ‘Marginal dietary copper deficiency induces cardiomyopathy in rats’; J. Nutr. 135:2130-2136, 2005.
  9. Elsherif L et al: ‘Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice’; J. Nutr. 134:855-860, 2004.
  10. Topuzoglu G et al: ‘Concentrations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomyopathy’; Biol. Trace Elem. Res. 95(1):11-17, 2003.
  11. Burch BE, Giles TD: ‘The importance of magnesium deficiency in cardiovascular disease’; Am. Heart J. 94:649-656, 1977.
  12. Weglicki WB et al: ‘Antioxidants and the cardiomyopathy of Mg-deficiency’; Am. J. Cardiovasc Pathol 4(3):210-215, 1992.
  13. Fruhwald FM et al: ‘A physiological oral magnesium supplement does not influence total serum magnesium, left ventricular ejection fraction and prognosis in patients with dilated cardiomyopathy’; Magnes. Res. 6(3):251-255, 1993.
  14. Poley JR et al: ‘Selenium deficiency and cardiomyopathy. Abstract’; J. Am. Coll. Nutr. 13(5):522, 1994.
  15. Yang FY et al: ‘Keshan disease – an endemic mitochondrial cardiomyopathy in China’; J. Trace Elem. Electrolytes Health Dis. 2(3):157-163, 1988.
  16. Collipp PJ, Chen SY: ‘Cardiomyopathy and selenium deficiency in a two-year-old girl. Letter’; N. Engl. J. Med. 304:1304-1305, 1981.
  17. Goldman IS, Kantrowitz NE: ‘Cardiomyopathy associated with selenium deficiency. Letter’; N. Engl. J. Med. 305:701, 1982.
  18. Yusuf SW et al: ‘Cardiomyopathy in association with selenium deficiency: a case report’; J. Parenter. Enteral Nutr. 30(2):173-174, 2006.
  19. Winter S et al: ‘The role of L-carnitine in pediatric cardiomyopathy’; J. Child. Neurol. [Canada] 10(suppl 2):2S45-2S51, 1995.
  20. Regitz V et al: ‘Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases’; Am. J. Cardiol. 65(11):755-760, 1990.
  21. Maresca P et al: ‘Positive action of propionyl-L-carnitine on mechanical performance of papillary muscle from Syrian hamsters with hereditary dilated cardiomyopathy’; Eur. J. Pharmacol. 287(3):303-307, 1995.
  22. Rizos I: ‘Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration’; Am. Heart J. 139(2 Pt 3):S120-S123, 2000.
  23. Folkers K et al: ‘Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10’; Proc. Natl. Acad. Sci. USA 82(3):901-904, 1985.
  24. Mortensen SA: ‘Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)’; Clin. Invest. 71(8 suppl):S116-S123, 1993.
  25. Langsjoen PH, Folkers K: ‘Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy’; Am. J. Cardiol. 65:521-523, 1990.
  26. Langsjoen PH et al: ‘Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10’; Proc. Natl. Acad. Sci. USA 82(12):4240-4244, 1985.